Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft versus host disease (GVHD) prevention in HLA matched related donor blood or marrow transplantation (BMT). This study will report the toxicities associated with this drug combination and also explore possible correlations between specific blood cell types and antibody production during this therapy.
Age
2–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Disease Categories: (one of the following)
* AML, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease
* AML, age 51-60 years of age, in first or subsequent remission or relapsed/refractory disease
* AML with multilineage dysplasia
* ALL, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease
* ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease
* CML Beyond 2nd chronic phase or in blast crisis
* MDS; Includes World Health Organization classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS
* Myeloproliferative disorders; MDS with poor long-term survival including myeloid metaplasia and myelofibrosis
* High risk NHL in first remission
* Relapsed or refractory NHL
* HL beyond first remission
Males and females of any ethnic background 2 - 60 years of age
Karnofsky Performance Status ≥ 70% or Lansky performance status \> 70% for patients \< 16 years of age.
Matched related donor identified: 6/6 HLA-A, B and DRB1
Willingness to take oral medications during the transplantation period
Ability to understand and the willingness to sign a written informed consent document
